药石科技(300725) - 2022年2月24日投资者关系活动记录表

Group 1: Business Overview - The company focuses on molecular building blocks and aims to expand its CDMO (Contract Development and Manufacturing Organization) business. In 2021, the company rapidly increased its workforce by hiring industry experts to enhance operational capabilities [2]. - The company has implemented a BAT business model (Business Development + Account Manager + Technical Leader) to improve service quality and efficiency in CDMO operations [2]. Group 2: Production Capacity and Facilities - The Zhejiang Huishi production base will release new production capacity in 2022, with the 501 workshop expected to produce 165m³, the 502 workshop 94m³, and the 503 workshop 171m³ by the end of the year [2]. - New workshops have introduced advanced technologies that significantly enhance production efficiency, with a focus on meeting complex early project demands in CDMO [3]. Group 3: Sales and Market Expansion - The company has expanded its BD (Business Development) team from 2 to 7 members in the U.S., with plans to grow to 10. Similar expansions are planned for Europe, Japan, and domestic markets to enhance CDMO business promotion [3]. - Approximately 70% of the company's revenue comes from overseas, with emerging biotech companies contributing more than large multinational pharmaceutical firms [3]. Group 4: Workforce and Recruitment - As of the end of last year, the company had over 1,700 employees and plans to add more than 400 new positions in 2022 across various departments [4]. - The new headquarters in Nanjing can accommodate 1,000 personnel, with additional space being sought for laboratory and personnel expansion [4]. Group 5: Financial Performance and Projections - The company's gross margin improved slightly in 2021 compared to 2020, primarily due to better cost control and project optimization [4]. - The overall trend indicates a decline in gross margins, aligning with industry averages, but the company aims to stabilize margins through innovative technologies and process optimizations [5]. - Capital expenditures are expected to exceed 1 billion yuan this year, with significant investments in new facilities [5].